Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 5/2019

Open Access 01-05-2019 | Geriatric Assessment | Original Article

Clinical factors associated with the therapeutic outcome of chemotherapy in very elderly cancer patients

Authors: Satoko Ito, Haruyuki Ito, Noriyuki Sato, Yasuo Hirayama, Toshihiko Kusakabe, Takeshi Terui, Kunihiko Ishitani

Published in: International Journal of Clinical Oncology | Issue 5/2019

Login to get access

Abstract

Background

The purpose of this study was to detect background factors that might be associated with the therapeutic and curative outcome of chemotherapy in elderly cancer patients aged over 75 years.

Methods

A retrospective study was conducted for elderly cancer patients aged over 75 years who had received more than 2 courses of chemotherapy at our hospital. We analyzed the relationships between RECIST outcome and background factors, such as age, sex, clinical TNM stage, pre-treatment history, ECOG performance status, serum albumin, and Charlson comorbidity index using logistic regression analysis.

Results

A total of 103 cancer patients aged over 75 years were analyzed in this study, including 28 with hematological neoplasia, 36 with gastrointestinal tract cancers, 25 with breast cancers, and 14 with other malignancies originating in various tissues. Seventy-one patients (69.1%) had a positive clinical outcome including RECIST CR (complete response), PR (partial response) and SD (stable disease). Multivariate analysis showed that a high serum albumin level of more than 3.5 g/dl and a Charlson comorbidity index score of less than 2 points were positively correlated with a favorable therapeutic outcome.

Conclusions

The results of the current study suggested that serum albumin level and comorbidity index are the principal clinical factors affecting therapeutic outcomes in elderly cancer patients receiving chemotherapy. In the future, these factors may make chemotherapy adaptations, continuity, and effectiveness easier to predict than GA screening.
Literature
1.
Ministry of Health, Labour and Welfare in Japan “Vital Statistics of Japan. Tokyo, Japan: Statistics and Information Department, Minister’s Secretariat, Ministry of Health and Welfare (2012) “Ministry of Internal Affairs and Communications “national census”, National Institute of Population and Social Security Research “Population Projections for Japan” (in Japanese)
2.
Decoster L, Van Puyvelde K, Mohile S et al (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 26(2):288–300CrossRefPubMed
3.
Hurria A, Dale W, Mooney M et al (2014) Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol 32(24):2587–2594CrossRefPubMedPubMedCentral
4.
Christman K, Muss HB, Case LD et al (1992) Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA 268(1):57–62CrossRefPubMed
5.
Sargent DJ, Goldberg RM, Jacobson SD et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15):1091–1097CrossRefPubMed
6.
Chen H, Cantor A, Meyer J et al (2003) Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 97(4):1107–1114CrossRefPubMed
7.
Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed
8.
Carreca I, Balducci L, Extermann M et al (2005) Cancer in the older person. Cancer Treat Rev 31(5):380–402CrossRefPubMed
9.
Extermann M, Aapro M, Bernabei R et al (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55(3):241–252CrossRefPubMed
10.
Droz JP, Balducci L, Bolla M et al (2010) Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU INt 106(4):462–469CrossRefPubMedPubMedCentral
11.
Puts MT, Hardt J, Monette J et al (2012) Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst 104(15):1133–1163CrossRefPubMed
12.
Wildiers H, Heeren P, Puts M et al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595–2603CrossRefPubMedPubMedCentral
13.
Hurria A, Gupta S, Zauderer M et al (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104(9):1998–2005CrossRefPubMed
14.
Kenis C, Decoster L, Van Puyvelde K et al (2014) Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol 32(1):19–26CrossRefPubMed
15.
Extermann M, Bolder I, Reich RR et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 118(13):3377–3386CrossRefPubMed
16.
Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465CrossRefPubMedPubMedCentral
17.
Alexandre J, Gross-Goupil M, Falissard B et al (2003) Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 14(1):36–41CrossRefPubMed
18.
Murry DJ, Riva L, Poplack DG et al (1998) Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 11:48–51CrossRefPubMed
19.
Ogino H, Hanibuchi M, Kakiuchi S et al (2016) Analysis of the prognostic factors of extensive disease small-cell lung cancer patients in Tokushima University Hospital. J Med Invest 63(3–4):286–293CrossRefPubMed
20.
Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D et al (2007) Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg oncol 14(2):381–389CrossRefPubMed
21.
Boonpipattanapong T, Chewatanakornkul S (2006) Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J Clin Gastroenterol 40(7):592–595CrossRefPubMed
22.
Siddiqui A, Heinzerling J, Livingston EH et al (2007) Predictors of early mortality in veteran patients with pancreatic cancer. Am J Surg 194(3):362–366CrossRefPubMed
23.
Lis CG, Grutsch JF, Vashi PG et al (2003) Is serum albumin an independent predictor of survival in patients with breast cancer? J Parenter Enteral Nutr 27(1):10–15CrossRef
24.
25.
Pal SK, Hurria A (2010) Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 28(26):4086–4093CrossRefPubMed
26.
27.
Neugut AI, Matasar M, Wang X et al (2006) Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 24(15):2368–2375CrossRefPubMed
28.
Asmis TR, Ding K, Seymour L et al (2008) Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26(1):54–59CrossRefPubMed
29.
Suzuki H, Hanai N, Nishikawa D et al (2016) The Charlson comorbidity index is a prognostic factor in sinonasal tract squamous cell carcinoma. Jpn J Clin Oncol 46(7):646–651CrossRefPubMed
30.
Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(8):733–742CrossRefPubMed
31.
Supriya G, Mohile W, Dale, Somerfield MR et al (2018) practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 36(22):2326–2347CrossRef
Metadata
Title
Clinical factors associated with the therapeutic outcome of chemotherapy in very elderly cancer patients
Authors
Satoko Ito
Haruyuki Ito
Noriyuki Sato
Yasuo Hirayama
Toshihiko Kusakabe
Takeshi Terui
Kunihiko Ishitani
Publication date
01-05-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 5/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-01385-8

Other articles of this Issue 5/2019

International Journal of Clinical Oncology 5/2019 Go to the issue

Original Article

Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy

Correction

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

Original Article

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases

Original Article

Risk factors for cardiovascular mortality in patients with colorectal cancer: a population-based study

Original Article

Interaction of H. pylori with toll-like receptor 2-196 to -174 ins/del polymorphism is associated with gastric cancer susceptibility in southern China

Original Article

c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits